Everest Medicines, a China-based biopharmaceutical company focused on the discovery, development, manufacturing and commercialisation of innovative medicines and vaccines, has announced that the Singapore Health Sciences Authority (HSA) has approved NEFEGAN for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression.
Everest Medicines Strengthens Management Team
Calliditas Announces FDA Grants an Seven-Year Orphan Drug Period for Nefecon
Everest Medicines Announces Acceptance of VELSIPITY® NDA in Macau
Everest Medicines to Announce Full-Year 2023 Financial Results on March 28
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
Everest Medicines Announces Termination of Agreements with Providence